eligibility_summary
Women with stage II-IV epithelial ovarian/fallopian tube/primary peritoneal cancer, NED or minimal disease after 1st-line therapy, >6 mo life expectancy. Candidate for IP port, tumor sample ≥1 cm, no active infection, apheresis access, agree to leukapheresis, ECOG 0-1, labs: ANC ≥1000, Plt ≥75k, Hb ≥8, Cr ≤2x ULN, bili ≤1.5x, AST/ALP ≤3x, not pregnant. Exclude CNS/above-diaphragm mets, recent therapy, autoimmune disease/immunosuppression, immunodeficiency, uncontrolled illness, recent other cancers, low malignant potential tumors (except ovarian pseudomyxoma), substance/psychiatric, or per PI.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
NCT03735589 (withdrawn) tests two autologous cellular immunotherapies in stage II–IV ovarian/fallopian tube/primary peritoneal cancer: (1) Alpha-type-1 polarized dendritic cells (alphaDC1) vaccine (biologic, intradermal). Mechanism: patient tumor–antigen–loaded, type-1–polarized DCs designed to enhance antigen presentation and drive Th1/CTL priming and boosting. (2) Autologous natural killer cell-like cytotoxic T lymphocytes (nCTLs) (biologic, intraperitoneal). Mechanism: ex vivo DC-sensitized CTLs with NK-like cytotoxic features to kill residual peritoneal tumor cells. Targets/pathways: tumor-associated antigen–specific CTLs, NK-like cytotoxic pathways, DC-mediated antigen presentation, type-1/Th1 immunity in the peritoneal tumor microenvironment.